News for BridgeBio Pharma Inc Stock (BBIO)

BridgeBio Pharma: The Hub-And-Spoke Model Is Complicated And Confusing

Seeking Alpha • 01/19/23

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

GlobeNewsWire • 01/04/23

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

GlobeNewsWire • 12/22/22

BridgeBio Pharma to Participate in November Investor Events

GlobeNewsWire • 11/09/22

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

Zacks Investment Research • 11/03/22

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

GlobeNewsWire • 11/03/22

Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know

Zacks Investment Research • 10/27/22

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

GlobeNewsWire • 10/17/22

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

GlobeNewsWire • 10/14/22

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

GlobeNewsWire • 10/13/22

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen's LUMAKRAS® (sotorasib)

GlobeNewsWire • 10/11/22

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

GlobeNewsWire • 10/07/22

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

GlobeNewsWire • 09/20/22

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

GlobeNewsWire • 08/18/22

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

GlobeNewsWire • 08/10/22

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research • 08/04/22

BridgeBio Pharma (BBIO) Moves to Buy: Rationale Behind the Upgrade

Zacks Investment Research • 07/29/22

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

GlobeNewsWire • 07/26/22

BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

PRNewsWire • 07/25/22

BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases

GlobeNewsWire • 07/21/22

BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley's Bakar BioEnginuity Hub

GlobeNewsWire • 07/21/22

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

GlobeNewsWire • 06/27/22

BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease

Benzinga • 06/22/22

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

GlobeNewsWire • 06/22/22

BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

GlobeNewsWire • 06/13/22